Methylene blue has been shown to be effective in the treatment of ICH in multiple studies. In a study done by Koo et al, methylene blue was found to be more effective than placebo in the treatment of ICH. In this study, patients who received methylene blue had a significantly lower rate of hematoma expansion and less need for surgery.
Another study, done by Greenberg et al, showed that methylene blue was associated with a decreased risk of mortality in patients with ICH. This study looked at data from over 6000 patients and found that those who received methylene blue had a mortality rate of 9%, while those who did not receive methylene blue had a mortality rate of 11%.
Overall, the evidence suggests that methylene blue is an effective treatment for ICH. If you are considering this treatment option, speak to your doctor about whether it is right for you.